PubMed Health⌕ Search

Biomedical subjects

A Sauter

Publications and source records attributed to A Sauter.

67 records · Page 4Linked to original sources

Determination of cholecystokinin tetrapeptide and cholecystokinin octapeptide sulfate in different rat brain regions by high-pressure liquid chromatography with electrochemical detection.

A method for the determination of cholecystokinins in biological material, based on high-pressure liquid chromatography with direct electrochemical detection (HPLC-EC), is described. Using this method, the levels of cholecystokinin tetrapeptide and octapeptide sulfate in rat brain cortex, hippocampus, striatum, and brain stem were measured and found to be comparable to those reported using radioimmunoassay methods. We show that HPLC-EC is sensitive enough to accurately determine neuropeptides in brain tissue without prior derivatization and is therefore, due to its simplicity, an attractive alternative to existing methods.

Animals↗

Distribution of PNMT and epinephrine in the medulla oblongata of normotensive and spontaneous hypertensive rats.

The distribution of the Epinephrine forming enzyme (PNMT) activity and Epinephrine (E) levels was investigated in the medulla oblongata of spontaneous hypertensive rats (SH-rats) and in two normotensive strains, namely Wistar Kyoto rats (WK-rats) and Wistar rats. The PNMT activity increases progressively from the caudal to rostral parts in the C1 and C2 regions of the medulla oblongata. The enzyme activity and the E levels are in all parts of the C1 and C2 regions higher in Wistar rats than in WK-rats. The PNMT activity in all parts of the C2 region (with the exception of the caudal region), and in the middle part of the C1 region is higher in SH-rats than in WK-rats. The E levels in the SH-rats are higher than in WK-rats in the mediocaudal parts of the C2 and C1 regions.

Animals↗

Comparative effectiveness of two extracerebral DOPA decarboxylase inhibitors in Parkinson disease.

In four patients with Parkinson disease, we compared carbidopa combined with levodopa (Sinemet) and benserazide combined with levodopa (Madopar). All of these patients had responded to treatment, first with levodopa and then with Sinemet; after 6 years two continued to show a good response, while two developed marked "on-off" phenomena. Clinically, Sinemet and Madopar were similar; however, DOPA levels were higher, but with a shorter half-life, on Madopar. The higher DOPA levels may have been offset by the shorter half-life, resulting in no clinical change. DOPA levels were lower and half-life was shorter in patients with on-off phenomena. These differences may be responsible in part for the on-off phenomena.

Aromatic Amino Acid Decarboxylase Inhibitors↗

[Abstinence behavior and plasma concentration of disulfiram in alcoholics after esperal implantation].

Abstinence behaviour after disulfiram implantation has been investigated in 21 chronic alcoholics. The blood levels of disulfiram and its metabolites, carbon disulfide (CS2) and reduced disulfiram (diethyldithiocarbamate) were determined and the blood levels of patients with implants were compared with those of patients receiving disulfiram orally. The blood levels in the implanted patients were significantly lower than those of the group taking disulfiram orally. No metabolites were detectable after 3 months, despite the sensitive method employed. Nevertheless, 14 of the 21 chronic alcoholics remained abstinent for 6 months after implantation. This result is probably due in the main to psychotherapeutic guidance.

Adult↗

Reduction of neural damage in irreversible cerebral ischemia by calcium antagonists.

Because of the complexity and cost of clinical investigations and the virtual lack of pharmacological leads, drugs for the treatment of strokes have to be tested extensively in animal models closely mimicking the human disorder. With the recent introduction of in vivo NMR imaging (MRI) and spectroscopy (MRS), it is now possible to evaluate the consequences of strokes and to monitor the effects of therapeutic interventions in animals with the same methodology as in humans. The appearance and evolution of brain infarcts in spontaneously hypertensive rats (SHR), after occlusion of the middle cerebral artery (MCA), were detected with MRI. In coronal sections through the rat brain, regions with increased MRI signal started to become discernible after 6 h and turned out to be largely necrotic already after 24 h, as revealed by histology. The location (fronto-parietal cortex, caudate-putamen) and total infarct size, as determined from MR images or histology, were highly reproducible. Posttreatment with the dihydropyridine calcium antagonist isradipine (PN 200-110), at a daily dose of 3 X 0.3 mg/kg sc, reduced the total infarct size by 30-40%, determined by quantitative MRI and confirmed by histology. Biochemical markers of necrosis, such as the increased brain wet wt, the levels of sodium, potassium, dopamine, and noradrenaline, were changed toward normal values. The functional consequences of these morphological effects of isradipine were reflected by the parallel improvement of a neurological score. Follow-up observations made by MRI and histology indicated that the morphological differences between treated and control animals were still present to the same extent after 2 wk and, therefore, seem to be permanent. In order to elucidate the putative mechanisms involved, the influence of calcium antagonists on cerebral blood flow (CBF) and high energy phosphates (HEPs) was investigated. CBF was measured quantitatively with [14C] iodoantipyrine in MCA-occluded SHRs. Although isradipine had no effect on CBF in the contralateral hemisphere, at a dose reducing infarct size, it increased the reduced blood flow in the lesioned hemisphere toward normal values. HEPs (PCr and ATP) as well as inorganic phosphate (Pi) and intracellular pH were measured noninvasively in the rat brain by 31P MRS using a surface coil. Under normal conditions, calcium antagonists had no effect on these parameters.(ABSTRACT TRUNCATED AT 400 WORDS)

Animals↗

The disability assessment for dementia scale: a 12-month study of functional ability in mild to moderate severity Alzheimer disease.

The Disability Assessment for Dementia (DAD) scale was developed and validated as a measure of functional ability in dementia. DAD results have been reported in Alzheimer disease (AD) randomized, controlled treatment trials of up to 6 months, but results beyond 6 months have yet to be described. SAB INT 12 was a randomized, double-blind, placebo-controlled, parallel-group study in mild to moderate AD that included DAD assessments at baseline, month 6, and month 12. One hundred forty-four patients with AD in the placebo arm of SAB INT 12 were followed up for 12 months. DAD scores were obtained at baseline (mean DAD = 70.1, SD = 22.2), 6 months (mean DAD = 63.7, SD = 25.2), and 12 months (mean DAD = 59.3, SD = 28.9). The rate of decline was consistent across the domains of basic activities of daily living (ADLs) and instrumental ADLs, as well as the scoring of initiation, planning, and organization. The decline in DAD total scores in mild to moderate AD averages about one point per month, which equates to the loss of one item on the DAD scale every 2 months.

Activities of Daily Living↗

Calcium antagonists reduce the extent of infarction in rat middle cerebral artery occlusion model as determined by quantitative magnetic resonance imaging.

The appearance and evolution of brain infarcts over 3 days following proximal occlusion of the left middle cerebral artery (MCA) in SHR rats were measured non-invasively by magnetic resonance imaging (MRI). Infarcts were clearly visible in coronal, T2 weighted brain sections, 24, 48 and 72 h after MCA occlusion in the left hemisphere, as areas of increased NMR signals. The infarcts were quantified by pixel counting in each section, the sum of 4 sections representing an accurate estimate of the total infarct size. The location and extent of infarction, determined by MRI, were found to be highly reproducible and correlated well with post-mortem histological and biochemical data. A neurological score, made every 24 h, paralleled the evolution of the infarct size, which culminated after 48 h. Pre- or post-treatment of MCA occluded rats with the dihydropyridine calcium antagonist PN 200-110 resulted in a substantial reduction of infarct size, determined by MRI 24, 48 and 72 h after infarction, compared to vehicle treated controls. These findings were corroborated by corresponding improvements of the neurological scores as well as histological and biochemical data. Post-treatment with nimodipine showed qualitatively similar effects. These results support the notion that calcium antagonists, through vascular and/or metabolic mechanisms, are effective in treating acute stroke. Since they were obtained in a chronic, relevant model of stroke with a method directly applicable also to humans, they should encourage further clinical studies with calcium antagonists.

Animals↗